About us
We are committed to bring an affordable variant of gene therapy for rare diseases to market. We have the knowledge and expertise in-house for achieving that and our business model is not focused on shareholder value and making excess profit. The first gene therapies for rare diseases have recently come to the market. But they are very expensive: the manufacturers charge millions of euros per patient.
